hotspot -WSS

hotspot

author：hotspot 2025-08-28 08:47:08 - browse：425

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： House looks to weaken Medicare negotiation

WSS

Biogen Alzheimer’s drug launch off to slow start

Congress gives doctors Medicare pay bump

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

How digital tools helped lower hypertension in marginalized patients

Senators start work on Medicare physician payment reform

Vaccine advisory panel ACIP left half staffed by HHS

explore

hotspot

explore

As demand for Covid shots wanes, Moderna seeks its next success

Clinical trials giant ICON acquires HumanFirst

At least 13 dead in Texas as scorching temps continue

House looks to weaken Medicare negotiation

Tori Bowie and the unacceptable rates of Black maternal death

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

FDA approval of Sarepta Duchenne genetic therapy gives me hope

House looks to weaken Medicare negotiation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: How biotech is using artificial intelligence

focus

Senators start work on Medicare physician payment reform

FDA does about

Key House Republican on health care plans exit from Congress

Medical mystery: When a cough is not just a cough

A disappointing year of Humira biosimilars

Medicare Advantage proposed rates disappoint insurers

focus

knowledge

knowledge

explore